• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of nevoid psoriasis with Secukinumab in a pediatric patient.

作者信息

Neema Shekhar, Mannu Anand, Vasudevan Biju, Bhatt Siddharth, Krishnan Lekshmipriya, Kashif A W

机构信息

Department of Dermatology, AFMC, Pune, India.

Department of Pathology, AFMC, Pune, India.

出版信息

Dermatol Ther. 2022 Jun;35(6):e15456. doi: 10.1111/dth.15456. Epub 2022 Mar 23.

DOI:10.1111/dth.15456
PMID:35302696
Abstract
摘要

相似文献

1
Successful treatment of nevoid psoriasis with Secukinumab in a pediatric patient.司库奇尤单抗成功治疗一名儿童患者的痣样银屑病。
Dermatol Ther. 2022 Jun;35(6):e15456. doi: 10.1111/dth.15456. Epub 2022 Mar 23.
2
Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis.接受司库奇尤单抗治疗的银屑病患者出现罕见复发：线状银屑病。
Dermatol Ther. 2020 May;33(3):e13346. doi: 10.1111/dth.13346. Epub 2020 May 3.
3
Clinical course and background of eight patients who discontinued secukinumab after achieving a score of 0 on the psoriasis area and severity index.八名患者在银屑病面积和严重程度指数达到0分后停用司库奇尤单抗的临床病程及背景
J Dermatol. 2021 Aug;48(8):e380-e381. doi: 10.1111/1346-8138.15948. Epub 2021 May 18.
4
Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis.司库奇尤单抗诱导的一名银屑病患者手掌部水疱脓疱性皮疹
Dermatol Ther. 2020 May;33(3):e13332. doi: 10.1111/dth.13332. Epub 2020 Apr 7.
5
Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study.司库奇尤单抗治疗中重度掌跖脓疱型银屑病148周的疗效和安全性：2PRECISE研究的扩展
J Am Acad Dermatol. 2021 Feb;84(2):552-554. doi: 10.1016/j.jaad.2020.06.038. Epub 2020 Jun 18.
6
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.一项评估司库奇尤单抗治疗中度至重度斑块状银屑病儿科患者疗效和安全性的3期开放标签、随机多中心研究：24周结果
J Am Acad Dermatol. 2022 Jan;86(1):122-130. doi: 10.1016/j.jaad.2021.08.066. Epub 2021 Sep 30.
7
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.司库奇尤单抗治疗指甲银屑病的临床疗效和疾病负担的影响：随机安慰剂对照 TRANSFIGURE 试验的 32 周结果。
Br J Dermatol. 2019 Nov;181(5):954-966. doi: 10.1111/bjd.17351. Epub 2019 Jan 16.
8
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.司库奇尤单抗：中重度儿童斑块状银屑病治疗药物。
Paediatr Drugs. 2021 Nov;23(6):601-608. doi: 10.1007/s40272-021-00476-w. Epub 2021 Oct 19.
9
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks.司库奇尤单抗对银屑病患者内皮功能障碍及其他心血管疾病参数的影响：52 周研究结果
J Invest Dermatol. 2019 May;139(5):1054-1062. doi: 10.1016/j.jid.2018.10.042. Epub 2018 Nov 30.
10
Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis.司库奇尤单抗成功治疗与斑块状银屑病相关的局灶节段性肾小球硬化症。
Ren Fail. 2022 Dec;44(1):826-830. doi: 10.1080/0886022X.2022.2073893.